My Account

Risk Management
Workers Comp & Safety
Employee Benefits
International
People
Events
BI Intelligence
Magazine
- Current Issue
- Past Issues
DEI Institute

Recent Quotes

View Full List

My Watchlist

Indicators

Business Insurance Index

Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

89.74 +0.64 (+0.72%)

Streaming Delayed Price Updated: 1:19 PM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

73 74 Next >

George Soros Loads Up On First Solar Calls: What Does He Know That Wall Street Doesn't? ↗

May 16, 2025

Soros Fund Management, in a surprise move, revealed a bold new bet on First Solar Inc., scooping up 1.6 million call options.

Via Benzinga

Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price ↗

May 16, 2025

Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.

Via Investor's Business Daily

Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda ↗

May 15, 2025

Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors.

Via Benzinga

P/E Ratio Insights for AstraZeneca ↗

May 14, 2025

Via Benzinga

What Does the Market Think About AstraZeneca? ↗

April 29, 2025

Via Benzinga

Earnings Scheduled For April 29, 2025 ↗

April 29, 2025

Via Benzinga

AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025

May 13, 2025

From AstraZeneca

Via Business Wire

Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say ↗

May 12, 2025

JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting...

Via Stocktwits

Topics ETFs Government Stocks

AstraZeneca Reports Positive Data From Cancer Drug Trial: Retail Sentiment Brightens ↗

May 09, 2025

The company noted that no new safety concerns were identified with the combination of Imfinzi and BCG induction and maintenance therapy in the trial.

Via Stocktwits

IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

May 09, 2025

From AstraZeneca

Via Business Wire

Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks ↗

May 08, 2025

Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.

Via Benzinga

Topics ETFs Government

Tempus AI Stock: Time to Double Down or Cut and Run?

May 08, 2025

Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point to significant upside potential.

Via MarketBeat

Topics Artificial Intelligence

ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11

May 07, 2025

From AstraZeneca

Via Business Wire

Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Model ↗

May 07, 2025

The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology."

Via Benzinga

Topics Artificial Intelligence

AstraZeneca Gets Approval For Oncology Drug To Treat Mantle Cell Lymphoma In EU: But Retail Sentiment Dips ↗

May 06, 2025

The approval is based on positive results from a phase 3 trial, which demonstrated that Calquence plus bendamustine and rituximab reduced the risk of disease progression or death by 27% compared to...

Via Stocktwits

AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma ↗

May 02, 2025

AstraZeneca's Breztri met primary goals in four asthma trials, including KALOS, LOGOS, LITHOS, and VATHOS, involving over 5,000 patients.

Via Benzinga

Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time. ↗

May 02, 2025

Via The Motley Fool

Topics Artificial Intelligence

AstraZeneca’s Breztri Therapy Meets Primary Goals In Late-Stage Trials To Treat Asthma: Retail’s Positive ↗

May 02, 2025

AstraZeneca said on Friday that the full results from the two trials will be shared with regulatory authorities and presented at an upcoming medical meeting.

Via Stocktwits

BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma

May 02, 2025

From AstraZeneca

Via Business Wire

AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million Penalty ↗

April 29, 2025

AstraZeneca posts Q1 revenue of $13.59 billion and a strong EPADS beat; oncology leads growth as China's tax probe and halts the Truqap trial in prostate cancer.

Via Benzinga

AstraZeneca Beat Earnings Views, But Sales Come In Light As Cancer Study Flops ↗

April 29, 2025

Shares were little moved despite a strong earnings beat.

Via Investor's Business Daily

Topics Earnings Government

NXP Semiconductors, Brinker International, Ultra Clean, Sanmina And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

April 29, 2025

Via Benzinga

US Stock Futures Edge Higher Tuesday: Expert Warns Of 'Perfect Volatility Storm' With Major Earnings And Economic Data Due This Week ↗

April 29, 2025

U.S. stock futures are trading flat on Tuesday early-morning, keeping with the broad index averages on Monday, as markets await clarity and more earnings reports to come in over the course of this...

Via Benzinga

AstraZeneca's Q1 2025 Financial Results

April 29, 2025

From AstraZeneca

Via Business Wire

Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom ↗

April 28, 2025

Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising...

Via Talk Markets

Topics ETFs Stocks / Equities

Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio? ↗

April 27, 2025

Top mid-cap stock performers last week: Ascentage Pharma, Ardagh Metal, Bitdeer Tech, Pegasystems, Impinj, Lufax, Tempus AI, Kymera Therapeutics.

Via Benzinga

Topics Artificial Intelligence

Tempus AI Stock Is Ripping Higher Wednesday: What's Fueling The Move? ↗

April 23, 2025

Tempus AI Inc (NASDAQ:TEM) shares are surging Wednesday after the company announced a multi-year collaboration with AstraZeneca PLC (NASDAQ:AZN) and Pathos AI.

Via Benzinga

Topics Artificial Intelligence

Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal

April 22, 2025

Cellectis, backed by AstraZeneca funding and a multi-year cash runway, is advancing its prioritized allogeneic CAR-T pipeline toward pivotal 2025 milestones.

Via MarketBeat

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients ↗

April 21, 2025

AstraZeneca's Enhertu combo improved progression-free survival in HER2+ metastatic breast cancer in a Phase 3 trial, showing promising early results.

Via Benzinga

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer

April 21, 2025

From AstraZeneca

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

73 74 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.

Information

About Us
Contact
Advertise
Privacy Policy
Terms & Condition